RVPH

Reviva Pharmaceuticals Holdings Inc

Add to Watchlist

Advanced Chart

0.399

-0.006(-1.481%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.420

Open

0.420

VWAP

0.40

Vol

1.55M

Mkt Cap

19.16M

Low

0.3922

Amount

624.26K

EV/EBITDA(TTM)

Total Shares

29.82M

14.09M

EV/OCF(TTM)

P/S(TTM)

Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

4 Analyst Rating

1716.59% Upside

Wall Street analysts forecast RVPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVPH is 7.25 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

1716.59% Upside

Current: 0.399

Low

3.00

Averages

7.25

High

14.00

1716.59% Upside

Current: 0.399

Low

3.00

Averages

7.25

High

14.00

D. Boral Capital

D. Boral

Buy

downgrade

$8 -> $3

2025-05-20

Reason

D. Boral Capital

D. Boral

Price Target

$8 -> $3

2025-05-20

downgrade

Buy

Reason

D. Boral Capital lowered the firm's price target on Reviva Pharmaceuticals to $3 from $8 and keeps a Buy rating on the shares. The firm cites near-term financing uncertainty for the target cut. While brilaroxazine continues to advance toward a potential NDA filing with key data expected in Q2 and the RECOVER-2 trial slated to launch mid-year, Reviva's cash position is insufficient to support these milestones, the analyst tells investors in a research note. D. Boral views dilution risk as high and models multiple equity raises.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$15 → $8

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15 → $8

2025-04-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$14 → $11

2025-01-22

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$14 → $11

2025-01-22

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$15

2025-01-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$15

2025-01-21

Maintains

Strong Buy

Reason

Roth MKM

Boobalan Pachaiyappan

Strong Buy

Initiates

2025-01-10

Reason

Roth MKM

Boobalan Pachaiyappan

Price Target

2025-01-10

Initiates

Strong Buy

Reason

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

2025-01-10

Reason

Maxim Group

Jason McCarthy

Price Target

2025-01-10

Upgrades

Hold

Strong Buy

Reason

Maxim analyst Jason McCarthy upgraded Reviva Pharmaceuticals to Buy from Hold with a $7 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH.O) is -0.72, compared to its 5-year average forward P/E of -5.90. For a more detailed relative valuation and DCF analysis to assess Reviva Pharmaceuticals Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.90

Current PE

-0.72

Overvalued PE

5.11

Undervalued PE

-16.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00